Annual report
2590.TEDINET S100XYDT
Period2025-01-21 → 2026-01-20
Filed2026-04-14
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥241.2bn | 2025-01-21 → 2026-01-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales |
| Revenue | ¥213.4bn | 2023-01-21 → 2024-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥160.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥162.6bn | 2021-01-21 → 2022-01-20d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.2bn | 2025-01-21 → 2026-01-20 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2024-01-21 → 2025-01-20 | Cons. | Operating income |
| Ordinary income | ¥1.5bn | 2025-01-21 → 2026-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-01-21 → 2024-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥591m | 2022-01-21 → 2023-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.7bn | 2021-01-21 → 2022-01-20d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥27.8bn | 2025-01-21 → 2026-01-20 | Cons. | Income before income taxes |
| Profit before tax | ¥7.9bn | 2024-01-21 → 2025-01-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥30.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.4bn | 2023-01-21 → 2024-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥507m | 2022-01-21 → 2023-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.0bn | 2021-01-21 → 2022-01-20d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥31.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss |
| Net income | ¥3.4bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss |
| Total assets | ¥162.8bn | at 2026-01-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥177.6bn | at 2024-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥164.2bn | at 2023-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥159.0bn | at 2022-01-20d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥97.9bn | at 2026-01-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥64.9bn | at 2026-01-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥91.5bn | at 2024-01-20v | Cons. | Net assets |
| Net assets / equity | ¥84.1bn | at 2023-01-20v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥83.3bn | at 2022-01-20d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2026-01-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.9bn | at 2026-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.2bn | at 2023-01-20v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥30.1bn | at 2022-01-20d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥11.4bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.1bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥12.1bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.0bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥300m | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-957.83 | 2025-01-21 → 2026-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.77 | 2023-01-21 → 2024-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-16.2 | 2022-01-21 → 2023-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.1 | 2021-01-21 → 2022-01-20d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,028.83 | at 2026-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,908.51 | at 2025-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,843.99 | at 2024-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,663.79 | at 2023-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,645.36 | at 2022-01-20d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 39.5% | at 2026-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2024-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2022-01-20d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -38.8% | 2025-01-21 → 2026-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2024-01-21 → 2025-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-01-21 → 2024-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -0.6% | 2022-01-21 → 2023-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2021-01-21 → 2022-01-20d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,375 | at 2026-01-20 | Cons. | Number of employees |
| Employees | 5,555 | at 2025-01-20 | Cons. | Number of employees |
| Employees | 5,182 | at 2024-01-20v | Cons. | Number of employees |
| Employees | 4,122 | at 2023-01-20v | Cons. | Number of employees |
| Employees | 4,029 | at 2022-01-20d | Cons. | Number of employees |
| Revenue | ¥5.0bn | 2025-01-21 → 2026-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.4bn | 2024-01-21 → 2025-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.3bn | 2023-01-21 → 2024-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥5.0bn | 2022-01-21 → 2023-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.8bn | 2021-01-21 → 2022-01-20d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥831m | 2025-01-21 → 2026-01-20 | Standalone | Operating income |
| Operating income | ¥972m | 2024-01-21 → 2025-01-20 | Standalone | Operating income |
| Ordinary income | ¥938m | 2025-01-21 → 2026-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2025-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2023-01-21 → 2024-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2022-01-21 → 2023-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-01-21 → 2022-01-20d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥25.8bn | 2025-01-21 → 2026-01-20 | Standalone | Income before income taxes |
| Profit before tax | ¥4.2bn | 2024-01-21 → 2025-01-20 | Standalone | Income before income taxes |
| Net income | −¥26.1bn | 2025-01-21 → 2026-01-20 | Standalone | Profit loss |
| Net income | ¥3.1bn | 2024-01-21 → 2025-01-20 | Standalone | Profit loss |
| Net income | ¥2.9bn | 2023-01-21 → 2024-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.9bn | 2022-01-21 → 2023-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2021-01-21 → 2022-01-20d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥97.4bn | at 2026-01-20 | Standalone | Assets |
| Total assets | ¥126.0bn | at 2025-01-20 | Standalone | Assets |
| Total assets | ¥124.8bn | at 2024-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.7bn | at 2023-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.2bn | at 2022-01-20d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥40.6bn | at 2026-01-20 | Standalone | Liabilities |
| Total liabilities | ¥43.3bn | at 2025-01-20 | Standalone | Liabilities |
| Net assets / equity | ¥56.7bn | at 2026-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.6bn | at 2025-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.4bn | at 2024-01-20v | Standalone | Net assets |
| Net assets / equity | ¥80.5bn | at 2023-01-20v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥80.1bn | at 2022-01-20d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥15.2bn | at 2026-01-20 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.7bn | at 2025-01-20 | Standalone | Cash and deposits |
| EPS (basic) | ¥-825.36 | 2025-01-21 → 2026-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.35 | 2024-01-21 → 2025-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.22 | 2023-01-21 → 2024-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.07 | 2022-01-21 → 2023-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.88 | 2021-01-21 → 2022-01-20d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2025-01-21 → 2026-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2024-01-21 → 2025-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-01-21 → 2024-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-01-21 → 2023-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2021-01-21 → 2022-01-20d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,789.67 | at 2026-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,614.69 | at 2025-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,618.07 | at 2024-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,564.03 | at 2023-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,559.09 | at 2022-01-20d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 58.3% | at 2026-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2025-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2024-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2023-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2022-01-20d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -37.5% | 2025-01-21 → 2026-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2024-01-21 → 2025-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.6% | 2023-01-21 → 2024-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2022-01-21 → 2023-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2021-01-21 → 2022-01-20d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 33,137,000 | at 2026-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,137,000 | at 2025-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2024-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2023-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2022-01-20d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2026-01-20 | Standalone | Number of employees |
| Employees | 51 | at 2025-01-20 | Standalone | Number of employees |
| Employees | 39 | at 2024-01-20v | Standalone | Number of employees |
| Employees | 26 | at 2023-01-20v | Standalone | Number of employees |
| Employees | 23 | at 2022-01-20d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-01-21 → 2026-01-20 | ¥1.0bn |
| Reconciling Itemsreconciling | depreciation | 2025-01-21 → 2026-01-20 | ¥949m |
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | segment assets | at 2026-01-20 | ¥34.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2026-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.8bn |
| Domestic Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥6.0bn |
| Domestic Beverage Businessreportable segment | employees | at 2026-01-20 | 3514 pure |
| Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥142.7bn |
| Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥142.5bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥119m |
| Domestic Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥43.9bn |
| Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥2.3bn |
| Dy Do Pharmareportable segment | capex | 2025-01-21 → 2026-01-20 | ¥20m |
| Dy Do Pharmareportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥61m |
| Dy Do Pharmareportable segment | employees | at 2026-01-20 | 12 pure |
| Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | segment assets | at 2026-01-20 | ¥892m |
| Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥321m |
| Food Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.3bn |
| Food Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥878m |
| Food Businessreportable segment | employees | at 2026-01-20 | 295 pure |
| Food Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2026-01-20 | ¥20.0bn |
| Food Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥487m |
| International Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.2bn |
| International Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥2.1bn |
| International Beverage Businessreportable segment | employees | at 2026-01-20 | 1147 pure |
| International Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥47.0bn |
| International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥7.5bn |
| Pharmaceutical Related Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.5bn |
| Pharmaceutical Related Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥1.1bn |
| Pharmaceutical Related Businessreportable segment | employees | at 2026-01-20 | 355 pure |
| Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥13.4bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥13.2bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥241m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2026-01-20 | ¥16.9bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥829m |
| —segment total | capex | 2025-01-21 → 2026-01-20 | ¥16.0bn |
| —segment total | depreciation | 2025-01-21 → 2026-01-20 | ¥10.2bn |
| —segment total | revenue | 2025-01-21 → 2026-01-20 | ¥241.6bn |
| —segment total | revenue external | 2025-01-21 → 2026-01-20 | ¥241.2bn |
| —segment total | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥368m |
| —segment total | segment assets | at 2026-01-20 | ¥128.6bn |
| —segment total | segment profit | 2025-01-21 → 2026-01-20 | ¥6.3bn |
| Reconciling Itemsreconciling | capex | 2024-01-21 → 2025-01-20 | ¥597m |
| Reconciling Itemsreconciling | depreciation | 2024-01-21 → 2025-01-20 | ¥796m |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | segment assets | at 2025-01-20 | ¥34.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2025-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥7.1bn |
| Domestic Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥5.6bn |
| Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥147.5bn |
| Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥147.4bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥86m |
| Domestic Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥74.8bn |
| Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥986m |
| Dy Do Pharmareportable segment | capex | 2024-01-21 → 2025-01-20 | ¥382m |
| Dy Do Pharmareportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥21m |
| Dy Do Pharmareportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | segment assets | at 2025-01-20 | ¥780m |
| Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2025-01-20 | −¥621m |
| Food Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| Food Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥834m |
| Food Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥20.7bn |
| Food Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥20.6bn |
| Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2025-01-20 | ¥21.0bn |
| Food Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| International Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥9.0bn |
| International Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.9bn |
| International Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥37.5bn |
| International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥5.1bn |
| Pharmaceutical Related Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥576m |
| Pharmaceutical Related Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.4bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥13.1bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥12.8bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥284m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2025-01-20 | ¥16.6bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥277m |
| —segment total | capex | 2024-01-21 → 2025-01-20 | ¥18.2bn |
| —segment total | depreciation | 2024-01-21 → 2025-01-20 | ¥9.7bn |
| —segment total | revenue | 2024-01-21 → 2025-01-20 | ¥237.6bn |
| —segment total | revenue external | 2024-01-21 → 2025-01-20 | ¥237.2bn |
| —segment total | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥378m |
| —segment total | segment assets | at 2025-01-20 | ¥150.8bn |
| —segment total | segment profit | 2024-01-21 → 2025-01-20 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,846
| Item | Context | Value | Unit |
|---|---|---|---|
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Other specific information if deemed necessary about application of equity method (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes additional information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding accumulated depreciation of property plant and equipment (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding business structure improvement expenses (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding income taxes and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Major components of assets and liabilities of consolidated subsidiary acquired by purchase of shares during reporting period (text) | CurrentYearDuration | Text · Plus | |
| Description of significant transactions not requiring use of cash or cash equivalents (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes derivatives consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes share options etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes asset retirement obligations consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes real estate for lease etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |